Quince Therapeutics (QNCX) Investor presentation summary

Mechanistic rationale and preclinical validation

• mTOR regulates smooth muscle proliferation, fibrosis, and inflammation, contributing to pulmonary hypertension pathobiology.

• Rapamycin inhibits mTOR, reversing vascular remodeling and improving hemodynamics in multiple preclinical PH models.

• Targeting mTOR addresses smooth muscle proliferation, endothelial dysfunction, and inflammatory cell infiltration in PH.

Clinical evidence and study design

• Early clinical studies with oral and IV sirolimus showed improvements in pulmonary vascular resistance (PVR) and 6-minute walk distance (6MWD) in PAH patients.

• Systemic oral rapamycin is limited by toxicity and poor lung exposure, prompting development of inhaled formulations.

• Phase 2a open-label trial (NCT05798923) evaluated inhaled LAM-001 in PAH and PH-ILD patients over 24 weeks, focusing on VO2 max, safety, and hemodynamics.

Patient characteristics and background therapy

• Ten patients enrolled, aged 47–80, with diagnoses including PAH, systemic sclerosis, idiopathic fibrotic NSIP, IPF, and pulmonary sarcoidosis.

• All patients were on stable background PH and/or ILD medications for at least 30 days prior to enrollment.